RemeGen Co.Ltd.
RC48(RemeGen Co., Ltd.)은 Gastric Cancer/Gastroesophageal Junction 표적 ADC로, Non-Muscle Invasive Bladder Cancer; HER2 영역에서 개발·상용화 중입니다. 작용기전: ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 56건의 관련 임상이 등록되어 있습니다. 차별점: novel PRaG3.
Gastric Cancer/Gastroesophageal Junction
Non-Muscle Invasive Bladder Cancer; HER2
Recruiting
ADCs) are complex molecules, and many fail clinically despite p
s
humanized anti-HER2 antibody to the potent microtubule-disrupting agent monomethyl auristatin E
novel PRaG3
ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis
payloads, and ADCs, validated using six ADCs (Enhertu, Kadcyla, Trodelvy, RC48, RN927C, and Datroway)
PD-1 inhibitors in high
resistance mechanisms and future combination strategies
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
RemeGen Co.Ltd.
RC48(RemeGen Co., Ltd.)은 Gastric Cancer/Gastroesophageal Junction 표적 ADC로, Non-Muscle Invasive Bladder Cancer; HER2 영역에서 개발·상용화 중입니다. 작용기전: ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 56건의 관련 임상이 등록되어 있습니다. 차별점: novel PRaG3.
Gastric Cancer/Gastroesophageal Junction
Non-Muscle Invasive Bladder Cancer; HER2
Recruiting
ADCs) are complex molecules, and many fail clinically despite p
s
humanized anti-HER2 antibody to the potent microtubule-disrupting agent monomethyl auristatin E
novel PRaG3
ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis
payloads, and ADCs, validated using six ADCs (Enhertu, Kadcyla, Trodelvy, RC48, RN927C, and Datroway)
PD-1 inhibitors in high
resistance mechanisms and future combination strategies
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.